BC Extra | Nov 25, 2019
Clinical News

Months after NASH failure, more woes for CymaBay's lead product on safety

CymaBay lost three quarters of its market value Monday after atypical histological findings prompted it to hold its lead program and discontinue two more trials, all developing seladelpar for liver indications. The $4.22 (76%) decline...
Items per page:
1 - 1 of 1